STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

The reverse stock split was approved by Cara ... 1.5 million (prior to giving effect to the closing of the Merger). The reverse stock split will not change the authorized number of shares ...

the expected number of shares of common stock to be issued and outstanding following the reverse stock split and the Merger, and other statements regarding management’s intentions, plans ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments ...

The combined entity will have a network of 38 hospitals and over 10,150 beds across 27 cities, making it one of the top three ...

Cara Therapeutics, Inc. (Nasdaq: CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

In an order issued on April 9, the Chandigarh-bench of the NCLT said that Pine Labs has taken approvals from all statutory ...